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299 Vitamin D status in pancreatic sufﬁcient children with cystic
ﬁbrosis − are we doing enough?
W.A. Orchard1, M. Brodlie1, M.F. Thomas1, G.A. Reeks1, H. McCabe1,
C. O’Brien1, D.A. Spencer1. 1Great North Children’s Hospital, Paediatric CF
Unit, Newcastle-Upon-Tyne, United Kingdom
Background: The proportion of pancreatic sufﬁcient children is increasing in many
UK paediatric cystic ﬁbrosis (CF) clinics, most probably as a consequence of
newborn screening. The importance of supplementation with fat-soluble vitamins
is widely recognised for children with pancreatic insufﬁciency, but the management
of pancreatic sufﬁcient children is less clear. The aim of this work was to examine
the current management and 25-hydroxyvitamin D (25-OHD) levels of pancreatic
sufﬁcient children in our regional centre.
Methods: Case records were reviewed of all children (n = 117). Pancreatic sufﬁ-
ciency and 25-OHD levels were noted along with vitamin D supplementation status.
Results: 16 pancreatic sufﬁcient children (median age 3.5 years, range: 7 months-
14 years) were identiﬁed, representing 14% of the clinic population. 7 patients
maintained on routine oral vitamin D supplementation due to previous low levels
had a median 25-OHD level of 69 (range: 40–124 nmol/L) compared to 61 nmol/L
(range: 13–124 nmol/L) in non-supplemented patients.
Conclusions: This study demonstrates that most children with pancreatic sufﬁciency
require supplementation to achieve current recommended levels. Monitoring of
serum 25-OHD levels is important in this group of patients. Careful attention
to diet and optimal exposure to sunlight are equally as important as vitamin
supplementation if current target levels are to be achieved. The most appropriate
vitamin management for this patient group needs to be established.
300 The effect of liver function on vitamin D (25-OHD) levels in
patients with cystic ﬁbrosis
M. Gautam1, R. Menon1, N. Jha1, J. Greenwood1, M.J. Ledson1, M.J. Walshaw1.
1Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
Introduction: The liver plays a vital role in the metabolism and hydroxylation
of vitamin D, and although the mechanisms for low circulating serum 25-OHD
concentrations in patients with chronic liver disease are complex, impaired hepatic
synthesis has been suggested as a cause. Overt liver involvement occurs in up to a
quarter of CF patients, who as a group are often deﬁcient in fat soluble vitamins
including vitamin D, raising the possibility that this may be inﬂuenced by their liver
function. To look at this further, we compared the relationship between vitamin D
levels and liver function in a CF population.
Methods: We looked at 611 paired blood samples (25-OHD and the liver function
tests ALT and ALP) performed on 205 adult CF patients (mean age 28 years,
mean BMI 23, 110 male). We deﬁned the degree of abnormality of liver function
dependent upon the ratio of normality.
Results: See table.
Liver function tests vs. Vitamin D
LFT Serum level Normal <3×
Normal
>3×
Normal
Pearson’s
coefﬁcient
(r)
p-value
ALT (IU/L) No. of samples 546 62 3 −0.14 <0.05
Average vitamin D
(ng/ml)
19 14 10
ALP (IU/L) No. of samples 381 222 8 −0.12 <0.05
Average vitamin D
(ng/ml)
19 18 9
Conclusions: The data demonstrate that a negative correlation between both ALT
and ALP and 25-OHD exists, even where liver function is mildly abnormal.
Although the cause for low circulating levels of Vitamin D synthesis is multi
factorial, this study provides objective evidence of a direct relationship between
Vitamin D and liver function. This raises the question whether the dose of vitamin D
supplementation should be increased in CF patients with signiﬁcantly altered liver
enzymes, warranting further research in this area.
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Objectives: The UK CF Trust issued a consensus statement relating to bone health
in 2007 recommending optimal target levels for 25-hydroxyvitamin D (25-OHD)
of 75–150 nmol/L. This was supported by evidence of an increase in parathyroid
hormone, a marker of bone turnover, when vitamin D levels were <75 nmol/L in
healthy adults. Our policy on vitamin D supplementation was changed following an
audit at our centre in 2008 where only 7% of patients had levels >75 nmol/L. The
aim of this study was to re-audit the vitamin D status of our pancreatic insufﬁcient
children in 2010.
Methods: Children were seen by the specialist CF dietician for education on
the change including optimal timing of supplementation with food and enzyme
therapy. Vitamin D3 supplementation increased by age: <1 year from 400 IU/day to
1,900 IU/day and >1 year from 800 IU/day to either 3,000 IU/day liquid or a weekly
20,000 IU tablet. Serum 25-OHD levels in 2010 (n = 101) were compared to 2008
(n = 97). Both audits used a 12 month sample to minimise the effects of seasonal
variation.
Results: The median serum 25-OHD level signiﬁcantly increased from 49 nmol/L
(range: 7−91 nmol/L) in 2008 to 72 nmol/L (range: 29–158 nmol/L) in 2010
(Wilcoxon test, W= 1606, p< 0.05). 45% of patients had levels >75 nmol/l in 2010.
No adverse effects were reported and no patient had hypercalcaemia.
Conclusions: This substantial increase in vitamin D supplementation resulted in
a signiﬁcant increase in the percentage of patients achieving target levels, but this
was still not reached in over half of our patients. Further consideration needs to be
given to the optimal dose and to the achievability of the new target.
302 Vitamin D supplementation in children with cystic ﬁbrosis:
sunshine, cholecalciferol and ergocalciferol
L. Homola1,2, A. Holcikova1,2, P. Mikolasek1,2, J. Pavelka1,2. 1Masaryk University,
Brno, Czech Republic; 2Faculty Hospital Brno, Brno, Czech Republic
The aim of the study was to evaluate vitamin D serum levels in children with
cystic ﬁbrosis (CF) without supplementation during a year and to compare efﬁcacy
of ergocalciferol (D2) and cholecalciferol (D3) in achieving sufﬁcient vitamin D
serum level in these patients. Children were from South Moravia. The region
has average 1,600 solar hours per year. 40 children with CF were enrolled,
mean age 7 years, all pancreatic insufﬁcient and with normal renal functions.
80 blood samples from studied group were obtained in periods without vitamin D
supplementation throughout all seasons from 2005 to 2009. Serum was tested for
25-hydroxycalciferol [25(OH)D] with ELISA. The relation between season and
25(OH)D results was evaluated. In 2010 patients were randomized into 2 groups.
The ﬁrst cohort took D2 5,000 IU 3 times per week, 15,000 IU/week in total. The
second cohort took D3 2000 IU daily, 14,000 IU/week in total. Supplementation
lasted 12 weeks in winter 2010. During the period ﬁnal blood samples were obtained
and tested for 25(OH)D. Efﬁcacy of D2 and D3 in the achievement of sufﬁcient
25OH serum level of 75 nmol/L (30 ng/mL) was compared with T-test. Results
from patients without supplementation demonstrated signiﬁcant relation to season.
90% of patients had sufﬁcient levels from May to September. All patients had
vitamin D insufﬁciency from December to April. Comparison of D2 and D3 in
achieving level of 75 nmol/L 25(OH)D proved signiﬁcantly higher effectiveness of
D3 (t-test: p< 0.001). D3 reached 86±23 nmol/L, D2 reached only 48±11 nmol/L.
Based on the results, vitamin D supplementation in South Moravia is necessary
during winter and D3 given daily should be preferred.
